- Home
- KZR vs ECOR Comparison
KZR vs ECOR Comparison
Compare KZR & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZR | ECOR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 48.6M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KZR | ECOR |
|---|---|---|
| Price | $7.29 | $9.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $6.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 118.8K | 112.3K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $32,032,000.00 |
| Revenue This Year | N/A | $33.60 |
| Revenue Next Year | N/A | $30.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 27.20 |
| 52 Week Low | $3.53 | $4.16 |
| 52 Week High | $7.55 | $9.68 |
Technical Indicators
Market Signals| Indicator | KZR | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 76.18 |
| Support Level | $7.25 | $4.66 |
| Resistance Level | $7.47 | N/A |
| Average True Range (ATR) | 0.11 | 0.75 |
| MACD | -0.02 | 0.37 |
| Stochastic Oscillator | 37.50 | 79.65 |
Price Performance
Historical ComparisonAbout KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About ECOR electroCore Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.